Bedrijfsoverzicht
Ensysce Biosciences, Inc. operates as a clinical-stage pharmaceutical entity focused on developing prescription drugs designed to address severe pain relief within the context of opioid misuse, abuse, and overdose in the United States. The company leverages its proprietary Trypsin Activated Abuse Protection (TAAP) platform, which is engineered to release clinically effective doses of medication in a manner that mitigates the risks associated with diversion or misuse. This organization functions within the Healthcare sector, specifically inside the Biotechnology industry, positioning it as a player in the development of novel therapeutic mechanisms for pain management. The company's market capitalization stands at $4.31M, supported by an annual revenue of $5.07M and a workforce consisting of 8 employees. These financial figures indicate that Ensysce Biosciences, Inc. is currently a micro-cap entity with a very small operational footprint, suggesting that the enterprise is likely in an early-stage development phase where revenue generation is prioritized over profitability, and the limited headcount reflects a lean, resource-efficient structure typical of clinical-stage biotechnology firms.
Financiële gezondheid
Ensysce Biosciences, Inc. reported a trailing twelve-month revenue of $5.07M, yet the company incurred a net loss of $-10,175,700, resulting in an EBITDA of $-10,234,413. The substantial discrepancy between the $5.07M revenue and the negative net income reveals a highly aggressive cost structure characterized by significant operating expenses that far exceed current sales, a common characteristic in the biotechnology sector during clinical development. The company generated free cash flow of $-4,417,688, which indicates a continuous burn rate that necessitates external capital raising or the utilization of existing cash reserves to sustain operations and fund further research. Analyzing the three key margin metrics, the gross margin is recorded at -104.8%, the operating margin at -147.8%, and the profit margin at -200.8%; these deeply negative figures signify that the cost of goods sold and total operating costs are exceeding total revenue, preventing any positive contribution to earnings before interest, taxes, depreciation, and amortization or net profit. On the balance sheet, the company holds $4.31M in cash against a debt obligation of $306,708, with a debt-to-equity ratio of 10.63, indicating a highly leveraged financial position relative to its equity base despite the relatively low absolute debt amount. The current ratio stands at 1.59, which suggests that the company possesses sufficient current assets to cover its short-term liabilities, maintaining a baseline level of short-term liquidity despite the cash burn. Furthermore, the return on equity is -324.9% and the return on assets is -98.1%, metrics that reveal that management has not yet achieved positive returns on the capital invested or utilized, reflecting the high-risk nature of clinical-stage development where losses are expected prior to product commercialization.
Waarderingsbeoordeling
The valuation metrics for Ensysce Biosciences, Inc. present a complex picture given the lack of profitability, with a trailing P/E ratio listed as N/A and a forward P/E of -0.21. The absence of a trailing P/E and the negative forward P/E imply that the market is pricing the stock based on future expectations of earnings turnaround rather than current profitability, as the negative forward P/E suggests projected earnings that are still insufficient to cover the current share price or indicate a negative earnings trajectory in the immediate forward outlook. The price-to-book ratio is 0.66, which indicates that the market values the company at a discount to its book value, suggesting that investors are not willing to pay a premium for the company's assets, likely due to the high risk associated with its clinical-stage status and the potential dilution of equity. Alternative valuation metrics include a price-to-sales ratio of 0.85 and an EV/EBITDA of 0.00; the price-to-sales ratio suggests the market assigns less than one dollar of equity value for every dollar of sales, while the zero EV/EBITDA reflects the inability to value the company using earnings-based multiples due to the negative earnings profile. The stock has exhibited significant volatility, with a 52-week high of $4.85 and a 52-week low of $0.31, meaning the current trading price sits at a specific point within this wide range, highlighting the speculative nature of the investment. The beta value is 1.14, which explains that the stock's price volatility is higher than the broader market, moving 14% more than the market index on average, reflecting the heightened sensitivity to market fluctuations typical of small-cap biotechnology stocks.
Growth & Income
Ensysce Biosciences, Inc. demonstrated a revenue growth rate of 44.4% year-over-year, while earnings growth is N/A due to the lack of positive earnings. The earnings growth cannot be compared to revenue growth because the company is currently unprofitable, which implies that the primary focus is on scaling revenue through clinical trials and potential partnerships rather than generating immediate profits. As a non-dividend payer, the company does not distribute a dividend yield, which is N/A, nor does it have a payout ratio as it is 0.0%; consequently, the company reinvests all available resources, including its cash reserves, directly into research and development to advance its TAAP platform and achieve clinical milestones. The overall growth and income profile is characterized by rapid revenue expansion driven by product development activities, but the absence of dividends and negative earnings indicate that shareholder returns are currently generated solely through potential capital appreciation rather than income distribution.